Proficio Capital Partners LLC boosted its holdings in Revvity, Inc. (NYSE:RVTY - Free Report) by 12,298.3% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 195,769 shares of the company's stock after buying an additional 194,190 shares during the period. Proficio Capital Partners LLC owned 0.16% of Revvity worth $21,850,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. Principal Financial Group Inc. grew its position in shares of Revvity by 3.1% during the third quarter. Principal Financial Group Inc. now owns 141,871 shares of the company's stock valued at $18,124,000 after purchasing an additional 4,263 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its position in shares of Revvity by 3.3% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 299,723 shares of the company's stock valued at $38,290,000 after purchasing an additional 9,473 shares in the last quarter. Victory Capital Management Inc. grew its position in shares of Revvity by 4.5% during the third quarter. Victory Capital Management Inc. now owns 59,860 shares of the company's stock valued at $7,647,000 after purchasing an additional 2,582 shares in the last quarter. Metis Global Partners LLC grew its position in Revvity by 6.5% in the third quarter. Metis Global Partners LLC now owns 7,825 shares of the company's stock worth $1,000,000 after acquiring an additional 481 shares in the last quarter. Finally, CIBC Asset Management Inc grew its position in Revvity by 8.2% in the third quarter. CIBC Asset Management Inc now owns 17,993 shares of the company's stock worth $2,299,000 after acquiring an additional 1,368 shares in the last quarter. Hedge funds and other institutional investors own 86.65% of the company's stock.
Wall Street Analyst Weigh In
RVTY has been the subject of several recent research reports. Sanford C. Bernstein lowered Revvity from an "outperform" rating to a "market perform" rating and set a $130.00 price target for the company. in a research report on Friday, January 10th. Barclays raised their price objective on shares of Revvity from $135.00 to $140.00 and gave the stock an "overweight" rating in a research note on Monday, February 3rd. Bank of America raised shares of Revvity from a "neutral" rating to a "buy" rating and set a $138.00 price target for the company in a research note on Friday, December 13th. KeyCorp lifted their price target on shares of Revvity from $132.00 to $145.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. Finally, Raymond James reaffirmed an "outperform" rating and set a $145.00 price target (up previously from $140.00) on shares of Revvity in a research note on Monday, February 3rd. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $136.25.
Check Out Our Latest Analysis on Revvity
Revvity Stock Down 0.6 %
NYSE:RVTY traded down $0.67 during trading hours on Tuesday, reaching $112.55. The company's stock had a trading volume of 965,569 shares, compared to its average volume of 845,286. The company has a market capitalization of $13.52 billion, a P/E ratio of 50.93, a price-to-earnings-growth ratio of 3.82 and a beta of 1.06. Revvity, Inc. has a 12 month low of $97.32 and a 12 month high of $129.50. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.03 and a current ratio of 3.60. The stock has a 50 day moving average price of $116.97 and a two-hundred day moving average price of $117.86.
Revvity (NYSE:RVTY - Get Free Report) last issued its quarterly earnings data on Friday, January 31st. The company reported $1.42 EPS for the quarter, topping analysts' consensus estimates of $1.37 by $0.05. Revvity had a net margin of 9.81% and a return on equity of 7.68%. During the same period in the prior year, the business earned $1.25 earnings per share. Equities analysts predict that Revvity, Inc. will post 4.94 EPS for the current fiscal year.
Revvity Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, May 9th. Shareholders of record on Friday, April 18th will be issued a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.25%. The ex-dividend date of this dividend is Thursday, April 17th. Revvity's dividend payout ratio is currently 12.67%.
Insiders Place Their Bets
In other news, insider Tajinder S. Vohra sold 5,492 shares of the business's stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $116.81, for a total transaction of $641,520.52. Following the sale, the insider now directly owns 19,652 shares of the company's stock, valued at $2,295,550.12. The trade was a 21.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Joel S. Goldberg sold 15,170 shares of the business's stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the sale, the insider now directly owns 33,400 shares in the company, valued at $4,232,782. This trade represents a 31.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.60% of the company's stock.
About Revvity
(
Free Report)
Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
See Also
Before you consider Revvity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Revvity wasn't on the list.
While Revvity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
